Answers are grounded in this paper and cite their sources.
Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [ 177 Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but its clinical use still relies on nonpersonalized, empirically chosen fixed schedules. Here, we develop a mechanistic, patient-personalizable mathematical model simulating mCRPC response and organ-at-risk toxicity during [ 177 Lu]Lu-PSMA RPT. The model integrates tumor growth dynamics, radiobiological response, and organ-resolved pharmacokinetics inferred from mass data and standardized uptake values obtained from positron emission tomography studies. Parameters were derived from the literature, although the framework allows personalization by fitting to patient-specific data, such as imaging and prostate-specific antigen levels. Analytical threshold analysis identified a critical activity scale governing net tumor control, while simulations of a representative virtual patient (VP) illustrated the model’s coupled tumor and activity dynamics. Global sensitivity analysis identified tumor growth, uptake, and radiosensitivity parameters as key drivers of interpatient variability. Using VP cohorts generated via stochastic parameter sampling, we conducted in silico trials and benchmarked the model against published dosimetry and survival data for [ 177 Lu]Lu-PSMA trials. Convergence testing supported the use of cohorts of 500 VPs for stable population-level estimates. We then explored dosing and scheduling strategies to quantify efficacy–toxicity trade-offs. Consolidated regimens with fewer, higher-activity injections improved overall survival (OS) in silico but increased toxicity, especially in kidneys. Cycle length had a weaker influence on OS within a 2–9 week window, while it clearly affected toxicity, whereas excessive delays (> 12 weeks) markedly reduced efficacy. These methodological findings illustrate how mechanistic modeling and in silico trials can inform the design and personalization of RPT regimens.
No takes yet. Share an insight, caveat, or question.
Italia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: